Covid-19 News

    Ivermectin saves India


    but not Kerala Mizoram


    #IndiaFightsCorona COVID-19
    www.mygov.in


    India CoV-19 figures constantly go down. And also constantly the vaccine terror state of Kerla is responsible for 50% of India's deaths and cases. (18.10.2021)

    Vaccination overall obviously has no influence on cases/deaths as 3/4 of India has no cases/deaths from CoV-19 since June 2021.

    Why India goes on with "vaccinating" an immune population will be one more crime against humanity we will have to judge soon.

    Also the late adapters of Ivermectin like Tamil Nadu or states (Maharashtra) with an inferior health system than the Uttar Pradesh one now clearly reached a bottom they can live with.


    How brutally vaccines did fail in India (Kerala, Mizoram) you can see from the case backlog (open cases) numbers.

    Quote from Zephir_AWT

    No one of five waves in Japan ended because of vaccines.

    Incorrect. The last one ended because of vaccines in Japan, Argentina, Chile, Canada and many other countries. Either that, or this was the most astounding coincidence in history. Furthermore, the number of deaths compared to infections in Japan was much lower in the last wave compared to previous waves, because the last wave (August 2021) began with about 20% of the population vaccinated, mainly old people.

    Quote from Fm1

    According to latest lab studies, China’s first aerosolized COVID-19 vaccine has showed an increase of 250- to 300-fold in neutralizing antibody levels after two rounds of inactivated vaccine administration, proving greater efficacy in using a combination of different types of vaccines to enhance effects.

    If this pans out it will be great for two reasons. First, because it works better. Second, because a surprisingly large number of people are afraid of needles. I did not think more than a few percent would refuse the vaccine for that reason, but I have read that the numbers are higher. I suppose if the disease were more virulent and if it were killing tens of thousands of people a day, more people would overcome the fear of needles and get vaccinated.


    The influenza vaccine is now available for children in a nasal form, which is great. I wish older adults could take it! I don't enjoy getting a shot. But it is the sort of thing people of my generation were taught we should never complain about, or even admit we don't like it. To admit I am a little afraid of needles would be downright embarrassing. I would be more afraid of my wife laughing at me for being a wuss than I am afraid of the needle.

    Quote from JedRothwell

    If this pans out it will be great for two reasons. First, because it works better. Second, because a surprisingly large number of people are afraid of needles. I did not think more than a few percent would refuse the vaccine for that reason, but I have read that the numbers are higher. I suppose if the disease were more virulent and if it were killing tens of thousands of people a day, more people would overcome the fear of needles and get vaccinated.


    The influenza vaccine is now available for children in a nasal form, which is great. I wish older adults could take it! I don't enjoy getting a shot. But it is the sort of thing people of my generation were taught we should never complain about, or even admit we don't like it. To admit I am a little afraid of needles would be downright embarrassing. I would be more afraid of my wife laughing at me for being a wuss than I am afraid of the needle.

    The west authorizing a Chinese vaccine has about the same chance as a snowball in hell. It's not about lives, it's about profit.

    Quote from Fm1

    The west authorizing a Chinese vaccine has about the same chance as a snowball in hell.

    I disagree. I believe there are a number of Chinese, Japanese and Indian drugs approved for use in the U.S. Just looking in my medicine cabinet, I find some from India and Israel. If the public becomes aware that there is a more effective COVID drug in China, it will demand access to it. It might be better to have it manufactured under license in the U.S., but I do not think it would be blocked altogether.

    Quote from JedRothwell

    I disagree. I believe there are a number of Chinese, Japanese and Indian drugs approved for use in the U.S. Just looking in my medicine cabinet, I find some from India and Israel. If the public becomes aware that there is a more effective COVID drug in China, it will demand access to it. It might be better to have it manufactured under license in the U.S., but I do not think it would be blocked altogether.

    I hope you are right.

    Quote from Wyttenbach

    Natural immunity gives you 100% protection from hospital or serious disease.

    Wyttenfact


    Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital
    Israelis who had an infection were more protected against the Delta coronavirus variant than those who had an already highly effective COVID-19 vaccine
    www.science.org


    For instance, the higher hospitalization rate in the 32,000-person analysis was based on just eight hospitalizations in a vaccinated group and one in a previously infected group.

    Quote from JedRothwell

    If the public becomes aware

    The public in USA has nothing to say. Once every 2-4 years they can elect = decide between two mafia members at best. As the current mafia wants US first and profit are mine they will never allow a Chinese vaccine.


    They just invent some fakes news about it and multiply it by NYT, W-Post, CNN etc.. as seen with Ivermectin or HCQ fake news.

    Quote from THHuxleynew

    the higher hospitalization rate in the 32,000-person analysis was based on just eight hospitalizations in a vaccinated group and one in a previously infected group.

    Her the ratio is about 5000:32 in favor of infection. O an infection is 100x better than a vaccine. The real infection protection rate might even be much higher as with Pfizer you actually multiply the risk to get CoV-19.


    See page 13, table 2. https://assets.publishing.serv…llance-report-week-41.pdf


    The vaccines give you no protection from a CoV-19 infection. Now it looks even the contrary is true. As said 70% of all people that got the same type of cancer chemo as the "Pfizer vaccine" developed worse than without chemo.


    It is easy to guess that within one year the whole world will talk about all the pitiable Pfizer victims. And all fact checkers will still tell you that this chemo's did work great...



    About the linked study::

    https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1.full.pdf

    As for symptomatic SARS-COV-2 infections during the follow-up period, 199 cases were recorded, 191 of which were in the vaccinated group and 8 in the previously infected group.


    This gives a factor of 25x (8 of 199) better protection from an infection with real symptoms.


    It turns out Chinese pharmaceuticals already dominate the U.S. market. I did not know this. See:


    Coronavirus Spurs U.S. Efforts to End China’s Chokehold on Drugs (Published 2020)
    The Trump administration says the U.S. is too dependent on China for vital drugs. But it’s unclear how much Washington can do to alter global supply chains
    www.nytimes.com


    QUOTE:


    "Chinese pharmaceutical companies have supplied more than 90 percent of U.S. antibiotics, vitamin C, ibuprofen and hydrocortisone, as well as 70 percent of acetaminophen and 40 to 45 percent of heparin in recent years, according to Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations."

    Accumulating Preclinical Evidence Turmeric Inhibits SARS-CoV-2—German Study


    Accumulating Preclinical Evidence Turmeric Inhibits SARS-CoV-2—German Study
    German infectious disease, virologist, and microbiologist research specialists led by Albert Krawczyk, Ph.D. from University of Essen’s West German
    trialsitenews.com




    German infectious disease, virologist, and microbiologist research specialists led by Albert Krawczyk, Ph.D. from University of Essen’s West German Centre of Infectious Diseases as well as University Hospital Essen’s Institute for Virology and team sought to investigate if herbal medicines with known antiviral properties had any meaningful impact on SARS-CoV-2, the virus behind COVID-19. One such target is turmeric root, used by Asian societies for cooking as well as in herbal medicine for thousands of years. It turns out the herb’s bioactive ingredient called curcumin exhibits a broad-spectrum antimicrobial activity according to the German scientists. In a recent study, the team tested the antiviral activities of “aqueous turmeric root extract, the dissolved content of a curcumin-containing nutritional supplement capsule, and pure curcumin against SARS-CoV-2.” The author’s recap that in a series of the early state, preclinical lab experiments using cell cultures (VERO E6 and human Calu-3) supernatants, turmeric root extract, dissolved turmeric capsule content, as well as pure curcumin successfully neutralize the novel coronavirus SARS-CoV-2 at subtoxic levels.


    Pedigreed German Research Institutes

    The German researchers represent prominent institutions including the University of Essen School of Medicine, the University Hospital Essen, Institute of Virology, Ruhr University Bochum, Department of Molecular and Medical Virology, School of Medicine as well as the Department of Molecular Biochemistry, Cell Signaling, and the University Hospital, LMU Munich’s Institute of Psychiatric Phenomics and Genomics (IPPG).


    What follows is a brief description of the herb, its history, and use followed by a summary of the study and findings.


    Turmeric Root Background

    Used for thousands of years as a complementary treatment of several diseases, its bioactive ingredients were first studied in the early 19th century. For example, by 1815 according to the authors, scientists such as Vogel and Pelletier isolated the turmeric root and identified the bioactive ingredient curcumin.


    Known as Curcuma longa, the herb Turmeric root is broadly used as a spice in Southeast Asia where it also happens to be broadly cultivated. Of note, the rhizome of Curcuma longa consists of several structurally related curcuminoids. The authors shared that anywhere from 60% to 75% of the curcuminoid content is made of up curcumin which also goes by the name diferuloylmethane. The authors share that the remaining fraction includes combinations of diferuloylmethane (20-25%) and bisdemethoxycurcumin (5-15%).


    In reviewing the herb’s properties, the authors refer to a number of studies indicating a broad spectrum of bioactivities including antioxidant, anti-inflammatory, antibacterial, antitumor, and hepatoprotective activities.


    Turmeric & SARS-CoV-2 Research Cases

    Several research teams have studied the use of turmeric as a possible agent to inhibit SARS-CoV-2. Recently, Brazilian researchers investigated the use of turmeric as an inhibiting force against the novel coronavirus. They looked to determine if the ingredient curcumin could potentially represent a new adjuvant therapy for COVID-19 therapy. Published in the peer review Frontiers in Pharmacology the researchers studied how the agent could “interfere at different times/points during the infection caused by SARS-CoV-2.”


    Indian researchers have also investigated the use of curcumin as a possible adjuvant therapy targeting SARS-CoV-2. In a recently published piece in Frontiers of Pharmacology research scientists from a handful of medical centers in India provided information in the article “Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial.”


    For the randomized controlled trial, a 30-bed dedicated COVID-Health Center (DCHC) in Maharashtra served as the participating trial site center. The study protocol called for two groups including 1) a study group of patients that received curcumin (525 mg) with piperine (2.5 mg) in a tablet form twice a day and 2) a control group that received a dose of probiotics twice a day.


    The study team reported in the peer review journal that “patients with mild to moderate, and severe symptoms who received curcumin/piperine treatment showed early symptomatic recovery” meaning COVID-19 symptoms such as fever, cough, sore throat breathlessness were reduced faster.


    The study team also found that participants in the study group generally fared better with “Less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group.” They also found that the study drug reduced the duration of hospitalization.


    German Preclinical Study Team Findings

    The German study team found that the turmeric compounds “effectively neutralized SARS-CoV-2 at subtoxic concentrations in Vero E6 and human Calu-3 cells.”


    Additionally, the preclinical, early-stage lab research provides some evidence that “curcumin treatment significantly reduced SARS-CoV-2 RNA levels in cell culture supernatants.” Contributing to an accumulating trove of data, the German team indicates that curcumin represents a “promising compound for complementary COVID-19 treatment.”


    Assuming randomized controlled trials replicate and verify the findings the authors post that an adjuvant therapy represents a compelling opportunity to help care for patients infected with SARS-CoV-2, particularly the mild-to-moderate home care cases—represents the vast majority (90%+) of cases.


    Lead Research/Investigator

    Albert Krawczyk, Ph.D. University of Essen’s West German Centre of Infectious Diseases as well as University Hospital Essen, Institute for Virology, Corresponding Author


    Call to Action: The authors recommend the design of randomized controlled trials to “vigorously test the effectiveness of complementary treatment of COVID-19 patients with curcumin-containing products.” Follow the link to read the entire study in the peer review Swiss journal MDPI.


    Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro
    Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19). The availability of…
    www.mdpi.com

    Curcumin as a Potential Treatment for COVID-19
    Coronavirus disease 2019 (COVID-19) is an infectious disease that rapidly spread throughout the world leading to high mortality rates. Despite the knowledge of…
    www.frontiersin.org


    Covid-19 news: Valneva reports positive results from vaccine trial

    Covid-19 news: Valneva reports positive results from vaccine trial
    The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential…
    www.newscientist.com


    A covid-19 vaccine made by Valneva produced stronger antibody responses and fewer side effects than the Oxford/AstraZeneca vaccine in a clinical trial, the French company has announced. The trial included more than 4600 participants in the UK, who were randomly allocated one of the two vaccines, while delta was the predominant coronavirus variant in circulation. The rate of covid-19 cases was similar in the two groups and no participants developed severe illness from covid-19.


    Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

    Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 – Valneva


    October 18, 2021

    • VLA2001 successfully met both co-primary endpoints
      • Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S)
      • Neutralizing antibody seroconversion rate above 95%
    • VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins.
    • VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine


    - - - - - - - - - - - - - - ---

    I'm not sure where comparator AZ stands compared to Pfizer/Moderna/J&J

    Louisiana Attorney General Jeff Landry Letter to Pharmacy Board: Do Not Block Ivermectin or HCQ


    Louisiana Attorney General Jeff Landry Letter to Pharmacy Board: Do Not Block Ivermectin or HCQ
    TrialSite recently reported on the efforts of Nebraska AG Douglas Peterson to ensure that physicians are allowed to, in their professional discretion, use
    trialsitenews.com


    TrialSite recently reported on the efforts of Nebraska AG Douglas Peterson to ensure that physicians are allowed to, in their professional discretion, use ivermectin and HCQ off-label for COVID-19 treatment. Twenty-four state AG’s have threatened to sue over federal vaccine mandates. In the meantime, another state AG also stepped into the COVID-19 regulation space. On September 7, Jeff Landry of Louisiana wrote his state’s pharmacy board to advise that they not interfere with COVID-19 prescriptions. We cannot locate the letter on Landry’s government website, but a copy is posted on Twitter.


    On September 27, The Blaze offered us some more details about Landry’s goals. “Never have pharmacists been allowed to practice medicine and get between a doctor and his patient,” Landry told The Blaze. “Most certainly not in the middle of a pandemic.” Predating Peterson’s actions, Landry was the first AG to publicly notify pharmacists not to block COVID medications such as ivermectin. The Louisiana AG’s letter was in response to an August memorandum from that state’s Board of Pharmacy entitled, “Do not Use Ivermectin to Treat of Prevent COVID-19.” The September 7 letter reminds the pharmacists that FDA has long approved off-label use of drugs by doctors, “when they judge that it is medically appropriate for their patient.” Landry cited the Louisiana Medical Practice Act, which bars pharmacists from diagnosing or treating illness, and he notes that they have effectively been doing this by requesting diagnoses from physicians before filling prescriptions. “Upon reviewing this act, I find nothing that would allow the board to second guess the sound medical judgment of a physician when it comes to prescribing legal drugs to their patients, nor do I see anything that allows pharmacists generally to object to off-label use of FDA approved drugs,” offered Landry.


    Big Chains Intruding into Doctor-Patient Relationship?

    When a Blaze reporter asked about pharmacists’ rights to deny contraception in some states, Louisiana’s AG noted, “I don’t know where their conscience was when they were giving out opioids like M&Ms—-Ivermectin is not even a scheduled drug. All of a sudden they found a conscience.” Per The Blaze, Landry thinks that pushing back against “woke” censorship of news about effective COVID-19 treatments is key to preserving both health and freedom: “What’s always been great about American health care is that we allowed our doctors to practice their trade freely and do what’s best for their patients. What’s happening now is that big chain pharmacies are determining whether to treat this virus. That was never, ever the job of the pharmacist. After verifying it’s a legitimate prescription by a licensed doctor, they no longer have any license to do anything but fill the prescription.”


    24-48 Hour Window

    The Blaze also reports that physicians in all 50 states have noted pharmacist resistance to filling certain prescriptions. “It’s not just ivermectin,” said Missouri ICU doctor Mollie James. “I’ve had patients refused for any reason. Pharmacists have told them the scripts were ‘flagged’ as for COVID and ‘kicked out’ all of the scripts. I’ve had pharmacists refuse to fill an antibiotic for someone because they ‘think we’re using it to treat COVID.'” As one who worked in NYC ICUs from early in the pandemic, Dr. James argues that treatment from “day one” is key. “I regularly have patients infuriated and in tears, because they are sick and scared to death they will end up in a hospital because they can’t get their medications. There is a predictable timeline, and if people are having trouble breathing, I have about 24-48 hours to get them treated or they will end up in a hospital on oxygen. I can get anyone meds in 3-5 days, but sometimes that’s not enough.”


    Candy and Hemlock

    Since the Landry letter, the pharmacy board updated its guidance and said that they have no policy about ivermectin. “As a reminder, pharmacists have the right to exercise discretion when presented with any prescription, including ivermectin,” offered Malcolm Broussard, executive director of the Louisiana Board of Pharmacy. Landry is still concerned, and he thinks there is a “war” on supply leading to scarcity of medications like ivermectin. This is leading to prices much higher than a generic off-patent drug should cost. And insurance firms are also “balking” at ivermectin prescriptions at a time when many patients can’t afford the prices at smaller boutique pharmacies. Landry also notes that pharmacies hand out vaccines “like candy,” while the Nobel-winning ivermectin is attacked, “like it’s hemlock.” Finally, the AG asks why: “Why would the government want to discourage doctors working with their patients to try to find drugs that can therapeutically heal American citizens, especially when they are more effective and cost-effective?”

Subscribe to our newsletter

It's sent once a month, you can unsubscribe at anytime!

View archive of previous newsletters

* indicates required

Your email address will be used to send you email newsletters only. See our Privacy Policy for more information.

Our Partners

Supporting researchers for over 20 years
Want to Advertise or Sponsor LENR Forum?
CLICK HERE to contact us.